The World’s Largest Gathering of IPF Drug Developers
The IPF Summit focuses exclusively on closing the translational gap between preclinical predictability and clinical attrition to accelerate the development of truly curative idiopathic pulmonary fibrosis (IPF) therapeutics.
Download the full event guide - use the link on this page.
With the 2019 conference expanding upon an even greater breadth and depth of content, you’ll hear three days of unrivalled scientifically driven and case-study based analysis and discussion, as together leading academia and biopharma advance the IPF drug development frontier.
Last year, over 90 of IPF’s expert drug developers came together to advance the standardisation of imaging, share clinical insights, and evaluate better recapitulating disease physiology in vitro exclusively for IPF.
“This was a superb meeting combining several emerging themes in IPF therapies and a dynamic mix of formal presentations with impromptu networking. All the speakers were excellent, and every session provided novel and important insight regarding IPF. The effort the speakers put into their presentations was evident. Great job!”
Ceders-Sinai Medical Center
Prices:
Gold: Conference and Workshop Day: USD 4696.0
Silver: Conference and 2 Workshops: USD 4097.0
Bronze: Conference Only: USD 2899.0
Workshops Individual: USD 699.0
Speakers: Ahmet Tutuncu, Respivant, Andrei Gudkov, Roswell Park Comprehensive Cancer Center, Bernt van den Blink, Promedior, Cory Hogaboam, Cedars-Sinai Medical Center, Dan Rose, Clinical Trials Transformative Initiative, Elias Kouchakji, FibroGen, Eric Lefebvre, Pliant Therapeutics, Fernando Martinez, Weill Cornell Medicine, Ganesh Raghu, University of Washington, Hans Brightbill, Genentech, Harry Karmouty- Quintana, McGovern Medical School, Jane Connor, AstraZeneca, Joe Arron, Genentech, John O’Neil, XYLYX, Karl Kossen, Indalo Therapeutics, Kevin Flaherty, University of Michigan, Komathi Stem, monARC Bionetworks, Majd Mouded, Biogen, Marc Ramis- Castelltort, Senolytic Therapeutics, Mary Salvatore, Mount Sinai Medical Center, Mehran Moghaddam, OROX BioSciences, Peter Schafer, Celgene, Rick Jack, Promedior, Robert Kaner, Weill Cornell, Rusty Montgomery, Miragen Therapeutics, Sonya Zabludoff, Nitto Denko, Stavros Garantziotis, National Institute of Environmental Health Sciences, Sunhwa Kim, Merck, Toby Maher, Imperial College London, Wolfgang Jarolimek, Pharmaxis, Yves Wyckmans, Janssen Pharmaceuticals
The IPF Summit focuses exclusively on closing the translational gap between preclinical predictability and clinical attrition to accelerate the development of truly curative idiopathic pulmonary fibrosis (IPF) therapeutics.
Download the full event guide - use the link on this page.
With the 2019 conference expanding upon an even greater breadth and depth of content, you’ll hear three days of unrivalled scientifically driven and case-study based analysis and discussion, as together leading academia and biopharma advance the IPF drug development frontier.
Last year, over 90 of IPF’s expert drug developers came together to advance the standardisation of imaging, share clinical insights, and evaluate better recapitulating disease physiology in vitro exclusively for IPF.
“This was a superb meeting combining several emerging themes in IPF therapies and a dynamic mix of formal presentations with impromptu networking. All the speakers were excellent, and every session provided novel and important insight regarding IPF. The effort the speakers put into their presentations was evident. Great job!”
Ceders-Sinai Medical Center
Prices:
Gold: Conference and Workshop Day: USD 4696.0
Silver: Conference and 2 Workshops: USD 4097.0
Bronze: Conference Only: USD 2899.0
Workshops Individual: USD 699.0
Speakers: Ahmet Tutuncu, Respivant, Andrei Gudkov, Roswell Park Comprehensive Cancer Center, Bernt van den Blink, Promedior, Cory Hogaboam, Cedars-Sinai Medical Center, Dan Rose, Clinical Trials Transformative Initiative, Elias Kouchakji, FibroGen, Eric Lefebvre, Pliant Therapeutics, Fernando Martinez, Weill Cornell Medicine, Ganesh Raghu, University of Washington, Hans Brightbill, Genentech, Harry Karmouty- Quintana, McGovern Medical School, Jane Connor, AstraZeneca, Joe Arron, Genentech, John O’Neil, XYLYX, Karl Kossen, Indalo Therapeutics, Kevin Flaherty, University of Michigan, Komathi Stem, monARC Bionetworks, Majd Mouded, Biogen, Marc Ramis- Castelltort, Senolytic Therapeutics, Mary Salvatore, Mount Sinai Medical Center, Mehran Moghaddam, OROX BioSciences, Peter Schafer, Celgene, Rick Jack, Promedior, Robert Kaner, Weill Cornell, Rusty Montgomery, Miragen Therapeutics, Sonya Zabludoff, Nitto Denko, Stavros Garantziotis, National Institute of Environmental Health Sciences, Sunhwa Kim, Merck, Toby Maher, Imperial College London, Wolfgang Jarolimek, Pharmaxis, Yves Wyckmans, Janssen Pharmaceuticals
